证券代码：688621 证券简称：阳光诺和 公告编号：2025-049 北京阳光诺和药物研究股份有限公司 自愿披露关于 STC007 注射液治疗腹部手术后疼痛 II 期临床试验数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，北京阳光诺和药物研究股份有限公司（以下简称"公司"或"阳光诺 和"）全资子公司成都诺和晟泰生物科技有限公司（以下简称"诺和晟泰"）自 主研发的 STC007 注射液（项目代号"STC007"）治疗腹部手术后的中、重度 疼痛的 II 期临床试验达成预期目标。现将相关情况公告如下： （一）基本情况 药品名称：STC007 注射液 主要研发阶段：II 期临床试验 临床试验通知书受理号：CXHL2200494 国 （二）STC007 临床试验情况 试验名称：一项初步评估 STC007 注射液治疗腹部手术后疼痛的有效性、安 全性和药代动力学特征的随机、双盲、安慰剂/阳性对照Ⅱ期临床研究。 受试者数量：156 例 研究目的：评估 STC007 注射液用于择期全身麻醉下行腹部腔镜手术受试者 术后镇痛 ...

Core Viewpoint - The clinical trial of STC007 injection for treating moderate to severe postoperative abdominal pain has met its expected goals, indicating potential for effective pain management in this area [1] Group 1: Clinical Trial Results - The Phase II clinical trial was conducted by Chengdu Nuoheshengtai Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, in collaboration with Huazhong University of Science and Technology [1] - A total of 156 subjects were involved in the trial across 20 research centers nationwide [1] - STC007 injection showed significant improvement in postoperative pain scores within 0-24 hours compared to the placebo group [1] - When compared to Tramadol hydrochloride injection, STC007 also demonstrated effective pain relief during movement for moderate to severe postoperative pain patients [1] Group 2: Safety and Tolerability - The overall safety and tolerability of STC007 injection were reported to be good [1] - No new safety signals were identified during the trial, and no serious adverse events occurred [1]

Group 1: Market Performance - Major indices experienced a strong rebound, with the Shanghai Composite Index rising by 0.7%, Shenzhen Component Index by 1.24%, and ChiNext Index by 1.37% [2] - Over 4,200 stocks in the two markets saw gains, with a total trading volume of approximately 1.19 trillion yuan [2] Group 2: Digital Currency and Software Sector - The digital currency and software sectors led the market rally, with notable stocks like Lakala (300773.SZ) and Sifang Jingchuang (300468.SZ) hitting the daily limit with a 20% surge [2] - New Guodu (300130.SZ) rose over 14%, while Feitian Chengxin (300386.SZ) and Shenzhou Information (000555.SZ) also saw significant increases of 12.84% and 10%, respectively [2] Group 3: Autonomous Driving and Intelligent Connected Vehicles - Stocks related to autonomous driving and intelligent connected vehicles surged, with companies like Fulongma (603686.SH) and Jintour Environment (001230.SZ) hitting the daily limit [3] - A strategic cooperation agreement was signed between Xiaoma Zhixing and Guangzhou Public Transport Group, focusing on autonomous vehicle services [3] Group 4: Innovative Pharmaceuticals - The innovative pharmaceutical sector remains active, with companies like Sanofi Guojian (688336.SH) rising over 12% [4][3] - The sector is supported by policy backing, global competitiveness, and improving fundamentals, with a focus on "innovation + internationalization" [4] Group 5: Automotive Sector - The automotive sector showed strong performance, with Jinlong Automobile (600686.SH) and Dongfeng Co. (600006.SH) both increasing by 10% [5] - The launch of new models by XPeng and supportive government policies in Fujian province are contributing factors to the sector's growth [5] Group 6: Weak Sectors - The precious metals and food processing sectors experienced declines, with companies like Western Gold (601069.SH) and Laiyifen (603777.SH) seeing significant drops [5]

Core Viewpoint - The company has approved the 2025 Restricted Stock Incentive Plan and conducted a self-examination regarding insider trading among those privy to the plan's information, confirming compliance with regulations and no insider trading activities [1][6][4]. Group 1: Incentive Plan Approval - The company held its 19th meeting of the second board and the 4th meeting of the Compensation and Assessment Committee on May 12, 2025, where the 2025 Restricted Stock Incentive Plan was approved [1]. - The plan was developed in accordance with relevant laws and regulations, ensuring confidentiality and proper registration of insiders [1][6]. Group 2: Insider Trading Self-Examination - The company conducted a self-examination of insider trading activities among individuals privy to the incentive plan's information during the six months prior to its public disclosure [2]. - Two individuals were found to have traded the company's stock during the self-examination period, but their actions were based on publicly available information, and there was no evidence of insider trading [4][5]. - The company confirmed that all other insiders did not engage in any stock trading during the self-examination period, ensuring compliance with regulations [5][6]. Group 3: Shareholder Meeting - The company held its second extraordinary general meeting on May 28, 2025, where all proposed resolutions, including those related to the incentive plan, were approved without any objections [9][11]. - The meeting was conducted in accordance with legal and regulatory requirements, with all board members present [10][13].

证券代码：688621 证券简称：阳光诺和 公告编号：2025-047 北京阳光诺和药物研究股份有限公司 关于公司 2025 年限制性股票激励计划内幕信息知情 人买卖公司股票情况的自查报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 5 月 12 日，北京阳光诺和药物研究股份有限公司（以下简称"公司" 或"阳光诺和"）召开第二届董事会第十九次会议、第二届薪酬与考核委员会第 四次会议，审议通过了《关于<北京阳光诺和药物研究股份有限公司 2025 年限制 性股票激励计划（草案）>及其摘要的议案》等议案，具体内容详见公司于 2025 年 5 月 13 日在上海证券交易所网站（www.sse.com.cn）上披露的相关公告。 根据《上海证券交易所科创板股票上市规则》《上市公司股权激励管理办法》 （以下简称"《管理办法》"）《科创板上市公司自律监管指南第 4 号—股权激 励信息披露》等法律、法规和规范性文件以及公司章程有关规定，公司对 2025 年限制性股票激励计划（以下简称"本次激励计划"）采取了充分必要的保密措 ...

北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 2025 年第二次临时股东会的法律意见 京天股字（2025）第 345 号 致：北京阳光诺和药物研究股份有限公司 北京阳光诺和药物研究股份有限公司（以下简称公司）2025 年第二次临时股 东会（以下简称本次股东会）采取现场投票与网络投票相结合的方式，现场会议于 2025 年 5 月 28 日 14:30 在北京市昌平区科技园区双营西路 79 号院 29 号楼公司会 议室召开。北京市天元律师事务所（以下简称本所）接受公司聘任，指派本所律师 参加本次股东会会议并对本次股东会进行见证，并根据《中华人民共和国公司法》 《中华人民共和国证券法》（以下简称《证券法》）《上市公司股东会规则》（以 下简称《股东会规则》）以及《北京阳光诺和药物研究股份有限公司章程》（以下 简称《公司章程》）等有关规定，就本次股东会的召集、召开程序、出席现场会议 人员的资格、召集人资格、会议表决程序及表决结果等事项出具本法律意见。 本所律师认为，本次股东会的召集、召开程序符合法律、行政法规、《股东会 规则》和《公司章程》的规定。 二、 出席本次股东会的人员资格、召集人资格 （一）出席本 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2025-048 北京阳光诺和药物研究股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 05 月 28 日 （二） 股东会召开的地点：北京市昌平区科技园区双营西路 79 号院 29 号楼公 司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 61 | | --- | --- | | 普通股股东人数 | 61 | | 2、出席会议的股东所持有的表决权数量 | 40,188,264 | | 普通股股东所持有表决权数量 | 40,188,264 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 36.7761 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 36.77 ...

Core Insights - The CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) sectors are crucial in advancing innovative drugs from laboratory to clinical application and large-scale production, with Chinese companies gaining significant market share due to enhanced technical capabilities and cost advantages [1][2]. Group 1: Strategic Opportunities in CXO - The CXO sector in China has experienced rapid growth over the past decade, evolving through four development stages, with a significant acceleration post-2015 due to increased demand for innovative drug development and the transfer of overseas industrial chains [2][3]. - The COVID-19 pandemic in 2020 catalyzed the upgrade of China's CXO industry, leading to a surge in participation in the global innovative drug supply chain [3]. Group 2: Growing Demand for Outsourcing in the Pharmaceutical Industry - The number of new drug registration clinical trials in China has been increasing annually, with a compound annual growth rate (CAGR) of 15% from 2019 to 2024, rising from 2,385 trials in 2019 to 4,884 in 2024 [4]. - The number of first-class new drugs listed in China has grown from 18 in 2020 to 49 in 2024, reflecting a CAGR of 28.4%, indicating a sustained upward trend in innovation capabilities [6]. Group 3: MAH System and Business Opportunities - The implementation of the MAH (Marketing Authorization Holder) system has separated drug production and marketing licenses, significantly boosting the CDMO market, with the number of B certificate enterprises increasing from 140 in 2021 to 1,349 by the end of 2024, a growth rate of 23% [10]. Group 4: Market Growth Rates - China's CRO market is projected to grow at a CAGR of 20.4%, increasing from 388 billion RMB in 2018 to 1,183 billion RMB in 2024, with expectations to reach 1,923 billion RMB by 2027 [12][14]. - The CDMO market in China is expected to grow at a CAGR of 37.8%, from 132 billion RMB in 2017 to 1,246 billion RMB in 2024, with projections to reach 3,559 billion RMB by 2030 [16][18]. Group 5: Rankings of CRO and CDMO Companies - The 2024 rankings of Chinese CRO companies include top-tier firms such as WuXi Biologics, Kanglong Chemical, and Tigermed, while the second tier features companies like Yino Science and Kingsray Biotech [22]. - The leading CDMO companies in 2024 include WuXi AppTec, Kelun Pharmaceutical, and WuXi Biologics, with a second tier comprising companies like Notch Biotech and Haier Pharmaceutical [24]. Group 6: Conclusion - Chinese CRO and CDMO companies have established comprehensive service capabilities across the pharmaceutical industry chain, transitioning from "Chinese service providers" to "global innovation partners," with a focus on technological innovation and compliance [26][27].

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant recovery in stock prices, attracting attention from brokers for research and investment opportunities [2] - The Tianhong Innovative Drug ETF (517380) has seen a net inflow of 3.6 million yuan, with a current scale of 389 million yuan as of May 26 [1] - The Tianhong ETF is the only product that comprehensively covers the innovative drug sector across A-shares and Hong Kong stocks, with a focus on the "Hengsheng Huasheng Hong Kong Innovative Drug Selected 50" index [1] Group 2 - The innovative drug industry is entering a new cycle of value reassessment due to a combination of policy, industry, and performance factors [2] - Longjiang Securities suggests that the previous valuation methods used during the bear market may no longer be applicable, indicating a need for a re-evaluation of the valuation system for innovative drug companies [2] - There has been significant interest from brokers, with nearly 60 companies in the pharmaceutical and biotechnology sector being researched this month, highlighting the sector's attractiveness [2]

Core Viewpoint - Sunshine Nuohuo has announced a significant asset restructuring plan to acquire 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd, aiming to enhance its capabilities in the pharmaceutical industry through resource integration and strengthen its full-chain layout for sustainable development [1][2]. Group 1: Acquisition Details - The acquisition will be executed through the issuance of shares and convertible bonds, focusing on integrating high-difficulty generic drug and innovative drug research, production, and sales [1]. - Langyan Life is a comprehensive pharmaceutical enterprise with established production capacity and channel resources in high-end chemical drugs and raw materials, covering critical clinical areas such as cardiovascular and anti-infection [1]. Group 2: Strategic Synergy - The collaboration between Sunshine Nuohuo's R&D strengths and Langyan Life's production capabilities is expected to create a synergistic effect, accelerating the technological upgrade of existing production capacity and providing a conversion platform for self-researched pipelines [2]. - Sunshine Nuohuo's innovative drug projects can quickly transition from laboratory to market using Langyan Life's production lines, while Langyan Life's mature products can benefit from Sunshine Nuohuo's R&D resources for process optimization and new indication development [2]. Group 3: Industry Context - The acquisition is positioned as a response to increasing policy changes in the pharmaceutical industry, which have heightened the need for industry chain division and integration [2]. - By pursuing vertical integration, Sunshine Nuohuo aims to enhance cost control across R&D, production, and sales, reducing reliance on external capacity and improving risk resilience amid the normalization of centralized procurement [2]. Group 4: Strategic Upgrade - This acquisition is a key move in Sunshine Nuohuo's strategic upgrade, reinforcing its "CRO + innovative R&D + pharmaceutical industry" layout, maintaining the professionalism of R&D services while enhancing the effectiveness of industrial transformation [3]. - The ongoing integration is expected to become a crucial support for optimizing the company's revenue structure [3].